Article

OptiMedica laser system makes U.S. debut

OptiMedica Corp. has launched its proprietary femtosecond laser platform (Catalys Precision Laser System) in the United States, with the first patient cases performed at the Mann Eye Institute and Laser Center in Houston.

Santa Clara, CA-OptiMedica Corp. has launched its proprietary femtosecond laser platform (Catalys Precision Laser System) in the United States, with the first patient cases performed at the Mann Eye Institute and Laser Center in Houston.

The platform combines a femtosecond laser, integrated 3-D optical coherence tomography imaging, and proprietary pattern scanning technology. The FDA cleared the system in December.

Mike Mann, MD, FACS, and Paul Mann, MD, are using the proprietary platform to perform laser capsulotomy and lens fragmentation during cataract surgery.

“We’ve been anxious and excited to get into laser cataract surgery since the technology first became available, but after considering all of the available competing systems, it became very clear we had to wait for [the proprietary system],” said Dr. Mike Mann. “[This system] represents the state of the art in laser cataract surgery and is the type of innovation Mann Eye patients have come to expect.”

“The U.S. launch of [this proprietary femtosecond laser platform] is a very exciting and rewarding milestone for OptiMedica, as we are now able to deliver the system’s precision and accuracy benefits to a vastly growing number of surgeons and patients around the world,” said Mark J. Forchette, OptiMedica’s president and chief executive officer.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.